We report a case of acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) after pandemic influenza (H1N1) vaccination. A 57-year-old man, who had been diagnosed with IPF in September 2008, was admitted to our hospital in December 2009 because of aggravation of dyspnea and fever two days after H1N1 vaccination. Chest computed tomography showed diffuse bilateral ground-glass opacities superimposed on preceding reticular opacities. We diagnosed AE-IPF. Corticosteroid and cyclophosphamide were effective. Although the efficacy of influenza vaccination in patients with chronic lung diseases is well established, physicians should keep in mind that influenza vaccination has the potential to cause AE-IPF.
Introduction
Influenza virus affects the upper and lower respiratory systems. Most healthy adults usually recover from the infection after 1 to 2 weeks, without medical treatment. However, significant morbidity and mortality has been seen in those with other medical conditions, such as chronic respiratory disorders. Influenza vaccination is widely used to prevent death from this virus in patients with these conditions (1) . Mild adverse events of the vaccination are common but more serious events are very rare. Here, we describe a patient with acute exacerbation of idiopathic pulmonary fibrosis (IPF) after pandemic influenza A (H1N1) vaccination. The patient experienced severe respiratory failure.
Case Report
A 57-year-old man was diagnosed as having IPF clinically according to the criteria of the American Thoracic Society/European Respiratory Society (ATS/ERS) international consensus statement (2) in September 2008. He was an exsmoker (60 pack-years) and denied any exposure to toxic chemicals. In September 2009, lung function tests showed a restrictive pattern (vital capacity [VC], 76.8%), with an impaired diffusion capacity (carbon monoxide transfer factor [DLCO], 53.2% of predicted), and data of arterial blood gas analysis was within normal limit (pH 7.407, PaO2 91.6 Torr, and PaCO2 39.8 Torr). He received the seasonal influenza vaccine (trivalent inactivated and unadjuvanted vaccine) in early November 2009. In late November 2009, chest X-ray showed no worsening of a preexisting abnormal opacity (Fig. 1A) . He received pandemic influenza A (H1N1) vaccine (monovalent inactivated and unadjuvanted vaccine), produced by Kaketsuken (Kumamoto, Japan), in early December 2009. At this point, there was no worsening of his respiratory condition, oxygen saturation was 95% while breathing room air, and body temperature was 37.4°C. He did not receive steroids or immunosuppressants before vaccination. Dyspnea on effort (British Medical Research Council dyspnea scale grade 5) and fever developed two days after pandemic influenza A vaccination and he was admitted to our hospital. Blood pressure was 132/83 mmHg, pulse rate was 104 beats/min (regular), and body temperature was 38.8°C. Fine crackles were audible in the bilateral lung bases on physical examination. Laboratory findings on admission (Table 1) were as follows: WBC, 10,800/mm 3 (neutrophils 82.9%, eosinophils 0.7%, basophils 0.2%, lympho- .71 mg/dL; KL-6, 2,072 U/mL; surfactant protein-D, 91.7 ng/mL; and surfactant protein-A, 37.8 ng/mL. Blood gas analysis while on 100% oxygen at 3 L/min showed hypoxia and hypocarbia (pH 7.476, PaO2 61.1 Torr, and PaCO2 30.7 Torr). Chest X-ray showed features of diffuse infiltrates in both lung fields (Fig. 1B) . Chest high-resolution computed tomography (HRCT) showed new diffuse bilateral ground-glass opacities superimposed on a background of reticular opacities and honeycombing with basal and peripheral predominance ( Fig. 1D , E). Cultures of endotracheal aspirate and blood showed no evidence of pulmonary infection or sepsis. Rapid influenza tests including nasal swab and endotracheal aspirate were negative. Echocardiography showed no evidence of left heart failure. These data confirmed a diagnosis of acute exacerbation of IPF according to the diagnostic criteria of the IPF Clinical Research Network (3). The patient's clinical course is shown in Fig. 2 . On day two after admission, the respiratory failure progressed and mechanical ventilation was applied. He was treated with steroid pulse therapy (1 g of methylprednisolone per day for 3 days), cyclophosphamide pulse therapy (500 mg of cyclophosphamide per day), sivelestat sodium hydrate, polymyxin Bimmobilized fiber column hemoperfusion (commonly used for the treatment of acute exacerbation of IPF in Japan), and antibiotics. After intensive treatment, the PaO2/FiO2 ratio improved from 168 to 403, and he was successfully weaned from mechanical ventilation on day 16 after admission. Chest X-ray and HRCT showed improvement of the groundglass opacities (Fig. 1C, F) . Prednisolone (1 mg/kg/day) and cyclosporine A (90 mg/day) were administered orally as maintenance therapy. Although his symptoms improved, long-term oxygen therapy was required.
Discussion
We report a case of acute exacerbation of IPF after pandemic influenza A (H1N1) vaccination. Current human vaccines are considered safe and effective by the medical community, for the general population as well as for patients with autoimmune rheumatic diseases (4, 5) . Nevertheless, post-vaccination adverse events, especially those of an autoimmune nature, have been described in rare cases (6, 7) .
In patients with IPF, prognosis is poor with a median survival time of 3 years from diagnosis, and death generally occurs from slowly progressive respiratory failure. Recently, it has been recognized that some patients without end-stage fibrosis have an acute exacerbation of IPF involving a rapid progression of disease (8). Kim et al (9) reported that the 1-year incidence of acute exacerbation was 8.5% in patients with IPF. The mortality rate was 81.8%, with the majority of patients dying within the first month. Although several case reports suggest that surgical lung biopsy can contribute to the onset of acute exacerbation of IPF (10), no specific etiologies have as yet been identified. In the present case, influenza A (H1N1) vaccination was the most likely cause of acute exacerbation. First, respiratory failure occurred shortly after the vaccination. As the patient received the seasonal influenza vaccine one month before the pandemic influenza (H1N1) vaccine, a second exposure to the same antigen might elicit a response within a shorter period (i.e., booster effect). Second, no other cause of deterioration was found, such as left heart failure, sepsis, or other infections. Influenza vaccination is reported to induce inflammatory cytokines, such as gamma interferon and interleukin-6, in humans (11, 12) . Bystander activation is a situation where enhanced cytokine production promotes the expansion of auto-reactive T cells, whose prior number had been insufficient to produce overt disease. In patients with IPF, although there have been no reports of mortality after influenza virus infection, we should reconsider the effectiveness and safety of influenza vaccination. In the present case, although there was no worsening of respiratory condition, physical examination showed low-grade fever before H1N1 vaccination. Therefore, we should be more cautious about the patient's condition before vaccination in terms of fever or other signs.
H1N1 Vaccina on
From October 19, 2009 to March 9, 2010, 22.8 million doses of H1N1 vaccine were distributed in Japan. To assess the safety profile of these vaccines, the Japanese Ministry of Health, Labour, and Welfare reviewed vaccine safety results from 402 serious adverse event reports (13) . In this series, although these reports provide only preliminary diagnoses, 19 reports (0.83 per 1 million H1N1 vaccine doses distributed) of acute respiratory deterioration of interstitial pneumonia, including the present case, were identified. On the other hand, from April 2006 to March 2009, 124.6 million doses of seasonal influenza vaccines were distributed in Japan. In this period, eight serious adverse events of interstitial lung disease (0.064 per 1 million seasonal influenza vaccine doses distributed) after seasonal influenza vaccination were identified. In clinical trials of the H1N1 vaccine products, most adverse events were mild and similar to those described after administration of seasonal influenza vaccines (14) . However, these clinical trials were limited in size and not designed to detect rare adverse events after vaccination. These data indicate that the reporting rate of acute deterioration of interstitial pneumonia after H1N1 vaccination was higher than that after seasonal influenza vaccination, while the reasons for this association remain unknown.
In conclusion, to our knowledge this is the first report to describe a case of acute exacerbation of IPF after pandemic influenza A (H1N1) vaccination. It is suggested that influenza vaccination, particularly with H1N1 vaccine, may contribute to acute deterioration of interstitial pneumonia. Although efficacy of influenza vaccination in patients with chronic lung diseases is well established, physicians should keep in mind that influenza vaccination has the potential to cause acute exacerbation of IPF.
